Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Nuclear receptors: emerging drug targets for parasitic diseases
Zhu Wang, … , Steven A. Kliewer, David J. Mangelsdorf
Zhu Wang, … , Steven A. Kliewer, David J. Mangelsdorf
Published February 6, 2017
Citation Information: J Clin Invest. 2017;127(4):1165-1171. https://doi.org/10.1172/JCI88890.
View: Text | PDF
Review Series

Nuclear receptors: emerging drug targets for parasitic diseases

  • Text
  • PDF
Abstract

Parasitic worms infect billions of people worldwide. Current treatments rely on a small group of drugs that have been used for decades. A shortcoming of these drugs is their inability to target the intractable infectious stage of the parasite. As well-known therapeutic targets in mammals, nuclear receptors have begun to be studied in parasitic worms, where they are widely distributed and play key roles in governing metabolic and developmental transcriptional networks. One such nuclear receptor is DAF-12, which is required for normal nematode development, including the all-important infectious stage. Here we review the emerging literature that implicates DAF-12 and potentially other nuclear receptors as novel anthelmintic targets.

Authors

Zhu Wang, Nathaniel E. Schaffer, Steven A. Kliewer, David J. Mangelsdorf

×

Figure 1

The DAF-12 signaling pathway.

Options: View larger image (or click on image) Download as PowerPoint
The DAF-12 signaling pathway.
(A) Under favorable environmental conditio...
(A) Under favorable environmental conditions, the free-living nematode C. elegans stimulates the production of steroid-like hormones (i.e., DAs) that activate the DAF-12 nuclear receptor. DAF-12 activation results in transcription of a metabolic and development gene network that promotes reproductive maturity. (B) In unfavorable conditions when DAs are not synthesized, DAF-12 functions as a transcriptional repressor of this gene network that results in developmental arrest and entry into the dauer diapause. In helminthic nematodes, this same pathway is believed to govern the development of infectious larvae and the resumption of their development into reproductive maturity after entering their hosts.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts